Where the technology stands — costs, approvals, scaling, and the path to mainstream availability
Cultivated meat — real animal meat grown from cells in bioreactors without slaughter — has progressed from a $330,000 burger in 2013 to regulated commercial availability in Singapore and the United States by 2023–2024. This is remarkable progress, but the technology still faces significant challenges before achieving the scale and cost that would drive mass adoption and meaningful reduction in conventional livestock production.
The welfare stakes are high: if cultivated meat achieves cost parity and consumer acceptance, it could fundamentally transform the relationship between humans and food animals — enabling the enjoyment of meat products without animal slaughter.
Eat Just received the world's first regulatory approval for cultivated chicken in Singapore. Products went on sale at 1880 restaurant in December 2020 — the world's first commercial cultivated meat sale. Singapore has remained a leader in cultivated meat regulatory development.
The US FDA issued its first "no questions" letter to Upside Foods in 2022, followed by USDA approval for Upside Foods and Good Meat in 2023. GOOD Meat cultivated chicken went on sale at a Washington DC restaurant — the first US commercial sale.
Multiple companies report costs below $25/kg in pilot production. The target for mass-market competitiveness with conventional chicken breast is approximately $5–10/kg. Continued progress on growth medium costs (particularly replacing animal serum with plant-based alternatives) is the key cost driver.
GOOD Meat has opened large-scale bioreactor facilities. Upside Foods completed a large pilot facility. The infrastructure build-out required for mass-scale production represents the next major investment challenge for the sector.
Despite significant cost reductions, cultivated meat remains substantially more expensive than conventional meat at current production scales. Achieving cost parity requires large-scale bioreactor production that requires massive capital investment and continued technical optimization of growth media and cell line efficiency.
Current commercial products are ground/unstructured products (nuggets, sausages). Whole-cut products (steak, chicken breast with realistic texture) require scaffolding technologies that are still developing. Most consumers' primary meat consumption includes whole cuts.
Only Singapore and the US have approved cultivated meat for sale. EU, UK, Australian, and other market approvals are in process but uncertain in timeline. Without broad regulatory approval, the market remains small and investment limited.
A significant portion of consumers express reluctance to try cultivated meat, citing "naturalness" concerns. Consumer acceptance research suggests that in-person tasting experiences substantially improve acceptance, but initial neophobia is a real adoption barrier.
Most analysts project that cultivated meat could achieve meaningful market penetration (5–10% of meat market) within 10–15 years under optimistic scenarios, with cost parity achieved for some products within 5–8 years. The welfare impact timeline depends significantly on continued investment, regulatory expansion, and consumer acceptance — all uncertain. But the trajectory is real, and each year brings the technology closer to the scale that would generate substantial reductions in conventional meat production and animal slaughter.